Cargando…
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
The R132H mutation of cytosolic isocitrate dehydrogenase (IDH1) is present in the majority of low grade gliomas. Immunotherapy in these tumors has an interesting, still unexploited, therapeutic potential, as they are less immunosuppressive than glioblastomas. Using site-directed mutagenesis we intro...
Autores principales: | Pellegatta, Serena, Valletta, Lorella, Corbetta, Cristina, Patanè, Monica, Zucca, Ileana, Riccardi Sirtori, Federico, Bruzzone, Maria Grazia, Fogliatto, Gianpaolo, Isacchi, Antonella, Pollo, Bianca, Finocchiaro, Gaetano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359524/ https://www.ncbi.nlm.nih.gov/pubmed/25849072 http://dx.doi.org/10.1186/s40478-014-0180-0 |
Ejemplares similares
-
P12. Combination of radiotherapy and chemotherapy with dendritic cell immunotherapy in glioblastoma patients induces NK and NKT cell responses
por: Pellegatta, S, et al.
Publicado: (2014) -
An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas
por: Yamamichi, Akane, et al.
Publicado: (2016) -
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
por: Tesileanu, C. Mircea S., et al.
Publicado: (2021) -
The prognostic IDH1(R132) mutation is associated with reduced NADP(+)-dependent IDH activity in glioblastoma
por: Bleeker, Fonnet E., et al.
Publicado: (2010) -
Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres
por: Patanè, Monica, et al.
Publicado: (2013)